Drug intelligence / Profile preview

isoflurane + analgesic drug

Development stage
Unknown
Lead developer
Sedana Medical
Modality
Small Molecules
Administration
Inhalation, Intravenous, Intramuscular, Subcutaneous, Oral
01

Overview

Isoflurane + analgesic drug refers to the combination of the inhalational general anesthetic isoflurane with an additional analgesic agent, typically used in both human and veterinary medicine to achieve balanced anesthesia. Isoflurane acts as a volatile anesthetic for induction and maintenance of general anesthesia by enhancing inhibitory neurotransmission (notably via GABA receptors) and reducing neuronal excitability. Analgesic drugs co-administered may include opioids (such as butorphanol or buprenorphine), alpha-2 agonists (such as xylazine or medetomidine), or other agents like ketamine, which provide pain relief and can reduce the required dose of isoflurane, improving cardiorespiratory stability during procedures[3][5][7]. The combination aims to optimize anesthesia depth while minimizing side effects such as respiratory depression.

02

Targets

ADRA2A (α2A)MOR (Mu opioid receptor)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)KCNA1 (Voltage-gated potassium channel subfamily A member 1)

Beyond the preview

Go deeper on isoflurane + analgesic drug.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isoflurane + analgesic drug.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call